Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 17/20 | 0.41 |
| ▸ | UGT1A4 | P22310 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4816603 | 0.84 | CYP19A1 (0.41) | CYP19A1UGT1A4PDE4DHDAC1HDAC6 | |
| SCHEMBL4815085 | 0.79 | HTT (0.39) | HDAC1HDAC6 | |
| SCHEMBL4816693 | 0.76 | CYP11B1 (0.52) | CYP19A1 | |
| SCHEMBL4820201 | 0.76 | CYP19A1 (0.41) | CYP19A1 | |
| SCHEMBL4811817 | 0.76 | CYP19A1 (0.50) | CYP19A1HDAC1HDAC6STS | |
| SCHEMBL4816893 | 0.74 | QPCT (0.34) | — | |
| SCHEMBL4815195 | 0.73 | CYP19A1 (0.50) | CYP19A1HDAC1HDAC6STS | |
| SCHEMBL4815901 | 0.71 | MAPT (0.42) | HDAC6 | |
| SCHEMBL4814816 | 0.71 | ALDH1A1 (0.44) | — | |
| SCHEMBL4815667 | 0.71 | WDR5 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1740579-B1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | ABBVIE INC. | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | PRKDC, PRKACA, PIK3C3 | CYP19A1 2367/4885UGT1A4 3629/4885PDE4D 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.